GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioXcel Therapeutics Inc (NAS:BTAI) » Definitions » Current Ratio

BTAI (BioXcel Therapeutics) Current Ratio : 1.87 (As of Sep. 2024)


View and export this data going back to 2018. Start your Free Trial

What is BioXcel Therapeutics Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. BioXcel Therapeutics's current ratio for the quarter that ended in Sep. 2024 was 1.87.

BioXcel Therapeutics has a current ratio of 1.87. It generally indicates good short-term financial strength.

The historical rank and industry rank for BioXcel Therapeutics's Current Ratio or its related term are showing as below:

BTAI' s Current Ratio Range Over the Past 10 Years
Min: 0.01   Med: 6.17   Max: 36.78
Current: 1.87

During the past 8 years, BioXcel Therapeutics's highest Current Ratio was 36.78. The lowest was 0.01. And the median was 6.17.

BTAI's Current Ratio is ranked worse than
68.86% of 1503 companies
in the Biotechnology industry
Industry Median: 3.69 vs BTAI: 1.87

BioXcel Therapeutics Current Ratio Historical Data

The historical data trend for BioXcel Therapeutics's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioXcel Therapeutics Current Ratio Chart

BioXcel Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Current Ratio
Get a 7-Day Free Trial 4.03 18.33 14.21 6.17 2.65

BioXcel Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.51 2.65 2.57 2.35 1.87

Competitive Comparison of BioXcel Therapeutics's Current Ratio

For the Biotechnology subindustry, BioXcel Therapeutics's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioXcel Therapeutics's Current Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioXcel Therapeutics's Current Ratio distribution charts can be found below:

* The bar in red indicates where BioXcel Therapeutics's Current Ratio falls into.



BioXcel Therapeutics Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

BioXcel Therapeutics's Current Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Current Ratio (A: Dec. 2023 )=Total Current Assets (A: Dec. 2023 )/Total Current Liabilities (A: Dec. 2023 )
=72.143/27.267
=2.65

BioXcel Therapeutics's Current Ratio for the quarter that ended in Sep. 2024 is calculated as

Current Ratio (Q: Sep. 2024 )=Total Current Assets (Q: Sep. 2024 )/Total Current Liabilities (Q: Sep. 2024 )
=47.792/25.557
=1.87

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioXcel Therapeutics  (NAS:BTAI) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


BioXcel Therapeutics Current Ratio Related Terms

Thank you for viewing the detailed overview of BioXcel Therapeutics's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


BioXcel Therapeutics Business Description

Traded in Other Exchanges
Address
555 Long Wharf Drive, New Haven, CT, USA, 06511
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
Executives
Richard I Steinhart officer: Chief Financial Officer 125 ELM STREET, NEW CANAAN CT 06840
Matthew T. Wiley officer: CHIEF COMMERCIAL OFFICER C/O FOAMIX PHARMACEUTICALS LTD., 2 HOLTZMAN ST, WEIZMANN SCIENCE PARK, REHOVOT L3 7670402
Javier Rodriguez officer: SEE REMARKS C/O BIOXCEL THERAPEUTICS, INC., 555 LONG WHARF DRIVE, NEW HAVEN CT 06511
Frank Yocca officer: Chief Scientific Officer 780 EAST MAIN STREET, C/O BIOXCEL THERAPEUTICS, INC., BRANFORD CT 06405
Vincent O'neill officer: Chief Medical Officer 2150 WOODWARD ST., SUITE 100, AUSTIN TX 78744
Vimal Mehta director, officer: CEO, President, Secretary 780 EAST MAIN STREET, C/O BIOXCEL THERAPEUTICS, INC., BRANFORD CT 06405
Krishnan Nandabalan director, 10 percent owner 228 VILLAGE POND ROAD, GUILFORD CT 06437
Alka Sood 10 percent owner 2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437
Michael James Aiello 10 percent owner 10 TEMPLETON ROAD, WALLINGFORD CT 06492
Pardeep Kumar Sood 10 percent owner 2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437
Vipin Agarwal 10 percent owner 2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437
Rashmi Agarwal 10 percent owner 2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437
Jatin Markand Patel 10 percent owner 2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437
Bina Jatin Patel 10 percent owner 2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437
Diwakar Jain 10 percent owner 2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437